News

Bayer expands in Down Under
Enlarge image

BusinessGermany

Bayer expands in Down Under

09.08.2012 - Bayer CropScience expands its R&D in Australia by the establishment of a breeding centre for stress- and drought resistant GM wheat and rapeseed.

The Monheim-based arm of German agri-biotech giant Bayer AG plans to build a new breeding centre near Horsham (Western Victoria). Bayer’s €12m investment for the new centre aims at developing new wheat and rapeseed varieties with higher yields and productivity tailored to Australian conditions. Australia ranks as the 3rd largest exporter for wheat and the 2nd largest for oilseeds.

"With the demand for wheat and oilseeds growing worldwide, we drive our efforts towards producing new high-yielding varieties that are better able to withstand pests, diseases and able to thrive under environmental stresses like drought," said Dr. Mathias Kremer, Head of the BioScience business unit at Bayer CropScience. The investment is part of Bayer’s plan to expand its wheat breeding stations in Asia and Latin America, which include huge consumer markets for wheat.

Construction of the new breeding centre will start in the coming months with first local breeding programs expected to yield results for Australian farmers within the decade, according to Bayer CropScience.

Agribiotechnology is a stragic growth field for the company. According to current market estimates of Companies & Markets the global agri-biotech market was valued at US$13.7bn and is estimated to hit US$14.4bn by the end of this year. Growing at an compound annual growth rate (CGAR) of 11.4% the agri-biotech market is to reach a value of US$24.8bn by 2017. Asia-Pacific represents the fastest growing agri-biotech market with a CGAR of 14% until 2015. Transgenic seeds, developed by Bayer CropScience as one of the key market players, make up the bulk of the market.

http://www.european-biotechnology-news.com/news/news/2012-03/bayer-expands-in-down-under.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%

FLOP

  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015